Background Gastroduodenal disorders of gut-brain interaction (DGBI) are prevalent in the paediatric population. Diagnostic pathways and subsequent treatment management approaches for children and young people can be highly variable, leading to diverse patient and clinical experiences. This study explores the DGBI diagnostic experiences of children and their families and the perspectives of clinicians in the New Zealand context. Methods Semi-structured interviews were conducted with 12 children with gastroduodenal DGBIs and their families and clinicians who care for children with DGBIs. Interviews were recorded, transcribed, and narratively analysed. Results Five children and family themes emerged: 1) how it all started, 2) the impacts symptoms had on child and family life, 3) their experiences with testing and investigations, 4) the perceptions and impacts of challenging clinical relationships, and 5) the uncertainness of trial and error treatments. Clinicians also identified five key themes: 1) navigating the complexity of presenting symptomology, 2) the challenging diagnostic investigation decision-making process, 3) navigating management and treatment approaches, 4) a lack of standardised clinical pathways, and 5) establishing therapeutic relationships with patients and families. Conclusion Children, their families, and clinicians confirmed the clinical complexity of DGBIs, the challenges of diagnosis and management, and the stress this places on therapeutic relationships. Clearer diagnostic pathways and new investigations that could provide improved identification and discrimination of DGBIs are needed to minimise the treat-test repeat cycle of care and improve health outcomes.

GOG and AG hold grants and intellectual property in the field of gastrointestinal electrophysiology. They are Directors in Alimetry Ltd. NZ. GOG is a Director in The Insides Company, and CK is an advisor for The Insides Company. ML, CNA and AG are employees or shareholders of Alimetry Ltd, NZ. The remaining authors have no conflicts to declare.

This study was supported by the Health Research Council of New Zealand.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study received ethical approval from the Auckland Health Research Ethics Committee, New Zealand (reference AH22600)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The data supporting the findings in presented in this manuscript. For more detail, data are available through the corresponding author (GH) upon reasonable request and ethical approval.